KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2016 - 2025)

Rigel Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $601000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $601000.0 for Q4 2025, changed 0.5% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 8.39% YoY), and the annual figure for FY2025 was $2.4 million, up 8.39%.
  • Depreciation & Amortization (CF) for Q4 2025 was $601000.0 at Rigel Pharmaceuticals, roughly flat from $603000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for RIGL hit a ceiling of $613000.0 in Q2 2024 and a floor of $237000.0 in Q1 2022.
  • Median Depreciation & Amortization (CF) over the past 5 years was $326500.0 (2023), compared with a mean of $402050.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): dropped 29.7% in 2022 and later skyrocketed 109.25% in 2024.
  • Rigel Pharmaceuticals' Depreciation & Amortization (CF) stood at $404000.0 in 2021, then decreased by 29.7% to $284000.0 in 2022, then grew by 3.17% to $293000.0 in 2023, then skyrocketed by 106.14% to $604000.0 in 2024, then decreased by 0.5% to $601000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $601000.0 (Q4 2025), $603000.0 (Q3 2025), and $607000.0 (Q2 2025) per Business Quant data.